EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis

Kaitlin G Whaley, Ye Xiong, Rebekah Karns, Jeffrey S Hyams, Subra Kugathasan, Brendan M Boyle, Thomas D Walters, Judith Kelsen, Neal LeLeiko, Jason Shapiro, Amanda Waddell, Sejal Fox und 11 weitere

Clinical Gastroenterology and Hepatology · 2023-05 · 21 (5) · 1338-1347

DOI: 10.1016/j.cgh.2022.08.016 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-05. Verfasst von Kaitlin G Whaley und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, U…. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: We aimed to model infliximab (IFX) pharmacokinetics (PK) in pediatric acute severe ulcerative colitis (ASUC) and assess the association between PK parameters, including drug exposure, and clinical response. METHODS: We studied a multicenter prospective cohort of hospitalized children initiating IFX for ASUC or IBD-unclassified. Serial IFX serum concentrations over 26 weeks were used to develop a PK model. We tested the association of PK parameter estimates with day 7 clinical response, week 8 clinical remission, week 26 corticosteroid-free clinical remission (CSF-CR) (using the Pediatric Ulcerative Colitis Activity Index), and colectomy-free survival. RESULTS: Thirty-eight participants received IFX (median initial dose, 9.9 mg/kg). Day 7 clinical response, week 8 clinical remission, and week 26 CSF-CR occurred in 71%, 55%, and 43%, respectively. Albumin, C-reactive protein, white blood cell count, platelets, weight, and antibodies to IFX were significant covariates incorporated into a PK model. Week 26 non-remitters exhibited faster IFX clearance than remitters (P = .013). However, cumulative IFX exposure did not differ between clinical response groups. One (2.7%) and 4 (10.8%) participants underwent colectomy by week 26 and 2 years, respectively. Day 3 IFX clearance >0.02 L/h was associated with colectomy (hazard ratio, 58.2; 95% confidence interval, 6.0-568.6; P < .001). CONCLUSIONS: At median higher-than-label IFX dosing for pediatric ASUC, baseline faster IFX CL was associated with colectomy and at week 26 with lack of CSF-CR. IFX exposure was not predictive of clinical outcomes. Higher IFX dosing may sufficiently optimize early outcomes in pediatric ASUC. Larger studies are warranted to determine whether sustained intensification can overcome rapid clearance and improve later outcomes. CLINICALTRIALS: gov identifier: NCT02799615.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansChildInfliximabGastrointestinal AgentsProspective StudiesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Anti-TNF Biological DrugInflammatory Bowel DiseaseTrough Serum Concentration

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Division of Digestive Diseases, Hepatology, Nutrition, Connecticut Children's Medical Center, Hartford, Connecticut.
  • Division of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia.
  • Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio.

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Whaley, K. G., Xiong, Y., Karns, R., Hyams, J. S., Kugathasan, S., Boyle, B. M., Walters, T. D., Kelsen, J., LeLeiko, N., Shapiro, J., Waddell, A., Fox, S., Bezold, R., Bruns, S., Widing, R., Haberman, Y., Collins, M. H., Mizuno, T., Minar, P., …, & Rosen, M. J. (2023). Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 21(5), 1338-1347. https://doi.org/10.1016/j.cgh.2022.08.016

Vancouver

Whaley KG, Xiong Y, Karns R, Hyams JS, Kugathasan S, Boyle BM, et al. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2023;21(5):1338-1347. doi:10.1016/j.cgh.2022.08.016

BibTeX
@article{Whaley2023,
  author = {Whaley, Kaitlin G and Xiong, Ye and Karns, Rebekah and Hyams, Jeffrey S and Kugathasan, Subra and Boyle, Brendan M and Walters, Thomas D and Kelsen, Judith and LeLeiko, Neal and Shapiro, Jason and Waddell, Amanda and Fox, Sejal and Bezold, Ramona and Bruns, Stephanie and Widing, Robin and Haberman, Yael and Collins, Margaret H and Mizuno, Tomoyuki and Minar, Phillip and D'Haens, Geert R and Denson, Lee A and Vinks, Alexander A and Rosen, Michael J},
  title = {Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {5},
  pages = {1338--1347},
  doi = {10.1016/j.cgh.2022.08.016}
}
Kostenlos starten →